Close Menu

San Antonio Breast Cancer Symposium

FLEX will include full transcriptome data paired with 800 data points from 10,000 patients, offering researchers the chance to study diverse patient subsets.

Despite promising Phase II data, ipatasertib failed to improve progression-free survival in TNBC patients with PIK3CA, AKT1, or PTEN tumor alterations.

An exploratory analysis in the ASCENT study showed improved survival with Gilead's antibody-drug conjugate regardless of patients' biomarker status.

A meta-analysis showed that early circulating tumor cell dynamics were associated with overall survival using Menarini Silicon Biosystems' CellSearch assay.